PMV Pharmaceuticals, Inc.

NASDAQ:PMVP

Biotechnology

Healthcare
$1.31 +3.91%

+$0.04 today

Market cap
$69.86M
Beta
1.36
P/E (TTM)
-0.8
EPS (TTM)
-$1.47
52W Low $0.96High $1.88

Volume 1.19M

Average 0.38M

Returns on capital

PMV Pharmaceuticals, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-74.2%

avg -15.3%

ROIC

-79.5%

avg -33.3%

ROA

-66.7%

avg -28.9%

Analysis

ROA is currently the strongest return metric at -66.7% versus its period average of -28.9%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

David H. Mack

Co-Founder, Chief Executive Officer, President & DirectorUSD 912.87K64——

Deepika Jalota

Chief Development OfficerUSD 653.07K49303.31K0.57%

Robert Ticktin

General Counsel, Chief Operating Officer & Company SecretaryUSD 612K64319.27K0.60%

Michael Carulli

CFO & Principal Financial & Accounting OfficerUSD 532.8K52240.00K0.45%

Arnold J. Levine

Co-Founder, Independent Director & Member of Scientific Advisory BoardUSD 140K8642.00K0.08%

Binh Vu

Senior Vice President of Drug Discovery & CMC————

Marc Fellous

Senior Vice President and Head of Clinical Development & Medical Affairs————

Philip Herman

Chief Commercial Officer—47——

Steve Dyott

Vice President of Marketing————

Tim Smith

Senior Vice President and Head of Corporate Development & Investor Relations————

Crystal Zuckerman

Vice President of Human Resources————

Laura De Leon

VP & Head of Clinical Development Operations————

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Jun 4, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

No open-market purchases or sales in the last 12 months.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A1 analysts
RevenueN/AN/AN/A
N/A1 analysts
Net IncomeN/AN/AN/A
N/A1 analysts
EBITN/AN/AN/A
N/A1 analysts

Analysis

Analysis will appear once historical growth or forward estimates are available for this company.

Competitors

Who does PMV Pharmaceuticals, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about PMVP's management, answered from reported figures.

Who manages PMVP?

PMV Pharmaceuticals, Inc. (PMVP) lists 12 active executives. The top listed executive is Arnold J. Levine, Co-Founder, Independent Director & Member of Scientific Advisory Board.

Are PMVP insiders buying or selling?

Recent insider activity shows net selling of $24.22M.